Skip to content

NAD+ and NMN for Neuropathy: Animal Findings & Human Trials

Rodent NAD+ findings have not established a neuropathy treatment. A 2026 human NR trial failed to prevent experimental nerve loss or improve 90-day regrowth.

By Marcus HaleLongevity Research Editor
Updated

4 min read · 11 sources

On this page

Peripheral neuropathy — the numbness, burning, and stabbing pain of damaged nerves, most often from diabetes or chemotherapy — is a problem with few good treatments. So when laboratory studies report that NAD+ precursors like NMN and nicotinamide riboside (NR) can reverse nerve damage, it's easy to see why supplement marketing seizes on it. The mechanism here is unusually compelling, too: NAD+ isn't just a generic "energy molecule" in nerves, it sits at the heart of a dedicated axon-survival program. That makes neuropathy one of the more scientifically interesting NAD+ stories.

The positive disease-reversal findings are in animals and cells. A 2026 placebo-controlled human NR study tested experimental skin-nerve damage and regrowth, without showing prevention of nerve loss or better regeneration at 90 days 11. That is a different result from both "untested in people" and "a proven neuropathy treatment."

Affiliate partner

Peter MD

Physician-prescribed injectable NAD+, sold as a course rather than a monthly plan

See Peter MD

Why NAD+ is mechanistically central to nerve survival

Most NAD+ claims rest on the vague idea that more NAD+ means more cellular energy. In nerves, the link is far more specific and well-characterized. When an axon is injured, it self-destructs through a controlled program called Wallerian degeneration — and the trigger for that program is a collapse in local NAD+. The enzyme SARM1, the central executioner of axon death, was shown to be itself an NAD+-cleaving enzyme: when activated, it chews up NAD+, and that NAD+ destruction is what drives the axon to degenerate 1. In other words, keeping NAD+ levels up inside a stressed nerve is, mechanistically, a way to hold off the very self-destruct switch that causes the nerve to die back.

The axon-survival mechanism

Nerve stress / injury

SARM1 activates and cleaves NAD+ — the axon self-destruct trigger

Raise NAD+ with NMN / NR

Aims to keep nerve NAD+ up and hold off the self-destruct program

Hoped-for: nerve protected

Animal findings; human nerve-model trial did not show sustained regeneration benefit

An unusually specific, well-characterized mechanism (SARM1-driven NAD+ collapse) — but the protective payoff is documented only in rodents.

That's why NAD+ precursors are a rational thing to test in neuropathy specifically — far more so than in most conditions they're marketed for. The hypothesis isn't hand-waving; it targets a defined molecular pathway. NAD+ also declines with age and metabolic stress in tissue generally 2, which dovetails with why diabetic and aging nerves might be NAD+-starved.

What was actually shown — and in whom

Here is the impressive part, stated precisely. In a 2024 study, NAD+ precursors reversed established experimental diabetic neuropathy in mice, restoring nerve function and mitochondrial health 3. An earlier study from the same group showed NAD+ precursors repaired mitochondrial function and prevented experimental diabetic neuropathy in diabetic animals 4, building on a broader understanding of how mitochondrial failure drives diabetic nerve damage 5. Separately, nicotinamide riboside was shown to oppose both type 2 diabetes and neuropathy in mice 6, and to improve diabetic enteric (gut) neuropathy by protecting the myenteric plexus in rats 7.

The chemotherapy-neuropathy data are similar in strength and species. NR relieved both the pain-sensitivity and the aversive, emotional dimensions of paclitaxel-induced peripheral neuropathy in female rats 8, and pharmacologically boosting the NAD+ salvage pathway protected neurons from chemotherapy-induced degeneration in cell and animal models 9.

Strength of evidence

  • NMN / NR → diabetic neuropathy (rodents)Strong evidence

    Reversed or prevented across multiple mouse and rat studies — preclinical only.

  • NR → chemo (paclitaxel) neuropathy (rodents)Strong evidence

    Relieved pain and aversive dimensions in rats; neuron protection in models.

  • SARM1 / NAD+ collapse → axon degenerationStrong evidence

    Well-characterized mechanism explaining why NAD+ matters in nerves.

  • NMN / NR → neuropathy in humansNone evidence

    A 2026 controlled NR study did not prevent experimental skin-nerve degeneration or improve 90-day regeneration.

Positive animal findings have not established a human neuropathy treatment; the 2026 experimental human study was negative at 90 days.

Read that list again and notice what every single entry has in common: mice, rats, or cultured neurons. Not one is a human therapy trial.

What the 2026 human nerve trial found

A double-blind, placebo-controlled Phase 2 study tested oral NR in an experimental model of capsaicin-induced skin-nerve degeneration and regeneration. NR did not prevent loss of epidermal sensory nerve fibers, and regeneration did not differ at the 90-day visit. A small difference at 60 days favored NR, but the authors described that finding as preliminary. They did not recommend NR for preventing neuropathy or improving nerve regeneration on these results 11.

This was an experimental skin-nerve model, not proof that NR treats established diabetic or chemotherapy-induced neuropathy. It also did not demonstrate a plasma NAD+ increase, although skin NAD+ increased slightly 11. The trial illustrates why blood biomarkers, local tissue exposure and a meaningful nerve outcome are separate questions.

For NMN, the cited prediabetes trial measured muscle insulin sensitivity, not nerve recovery 10. The positive mouse findings therefore remain a reason for research, not evidence to promise reversal of a person's neuropathy.

What this means if you have neuropathy

  • The mechanism is real and specific: NAD+ depletion via SARM1 drives axon self-destruction, so maintaining NAD+ is a logical nerve-protection strategy 1.
  • The preclinical data are genuinely strong — NMN and NR reversed or prevented diabetic and chemo neuropathy across multiple mouse and rat studies 346789.
  • The human result is not a demonstrated treatment benefit: the 2026 NR trial did not prevent experimental nerve loss or improve 90-day regeneration 11.
  • Neuropathy has real, established medical management — so NMN or NR is not a substitute for seeing a clinician, controlling blood sugar in diabetes, or using proven symptomatic treatments.

The fair verdict: NAD+ precursors for neuropathy are a research hypothesis with positive animal findings and a disappointing early human experiment, not a treatment you can rely on today. If you're considering supplementing anyway, do it as an adjunct discussed with your clinician — not as a replacement for care — and understand the broader picture first. For where NAD+ supplementation is genuinely supported versus merely hoped-for, see our pillar guide to NAD+ therapy evidence, the separate clinical evidence for NAD+ (NR) for Parkinson's, the side effects to know before high-dose precursors, and how products and providers compare on our NAD+ rankings hub.

Frequently asked questions

Can NMN or NR reverse neuropathy?

Positive reversal findings are from rodent models. A 2026 placebo-controlled human NR experiment did not prevent capsaicin-induced skin-nerve loss or improve regeneration at 90 days. This does not establish NR as a treatment for clinical neuropathy.

Why do researchers study NAD+ in nerves?

SARM1 can break down NAD+ during axon injury, linking local NAD+ metabolism to nerve degeneration. That mechanism supports research, but taking a precursor has not been shown to deliver a reliable clinical neuropathy benefit.

Are there human trials?

Yes. A 2026 double-blind controlled NR trial studied experimental skin-nerve degeneration and regeneration. Its main findings did not support nerve protection or improved 90-day regeneration. That model differs from established diabetic or chemotherapy-related neuropathy.

Should NR or NMN replace neuropathy care?

No. These supplements have not established a clinical treatment benefit and should not replace evaluation or management of the cause of neuropathy. Discuss any supplement with your treating clinician.

References

  1. Essuman K, Summers DW, Sasaki Y, et al. (2017). The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. Neuron. https://pubmed.ncbi.nlm.nih.gov/28334607/
  2. Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. https://pubmed.ncbi.nlm.nih.gov/33353981/
  3. Chandrasekaran K, Choi J, Salimian M, et al. (2024). NAD+ Precursors Reverse Experimental Diabetic Neuropathy in Mice. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/38256175/
  4. Chandrasekaran K, Salimian M, Konstantopoulos P, et al. (2022). NAD+ Precursors Repair Mitochondrial Function in Diabetes and Prevent Experimental Diabetic Neuropathy. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/35563288/
  5. Chandrasekaran K, Anjaneyulu M, Choi J, et al. (2019). Role of mitochondria in diabetic peripheral neuropathy. International Review of Neurobiology. https://pubmed.ncbi.nlm.nih.gov/31208524/
  6. Trammell SAJ, Weidemann BJ, Chadda A, et al. (2016). Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/27230286/
  7. Costa DVS, Bon-Frauches AC, Silva AMHP, et al. (2023). Nicotinamide Riboside Improves Enteric Neuropathy in Streptozocin-Induced Diabetic Rats Through Myenteric Plexus Neuroprotection. Digestive Diseases and Sciences. https://pubmed.ncbi.nlm.nih.gov/36920665/
  8. Hamity MV, White SR, Walder RY, et al. (2017). Nicotinamide riboside relieves nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats. Pain. https://pubmed.ncbi.nlm.nih.gov/28346814/
  9. Liu HW, Smith CB, Schmidt MS, et al. (2018). Pharmacological bypass of NAD+ salvage pathway protects neurons from chemotherapy-induced degeneration. Proceedings of the National Academy of Sciences. https://pubmed.ncbi.nlm.nih.gov/30257945/
  10. Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. https://pubmed.ncbi.nlm.nih.gov/33888596/
  11. Thomas S, Ben-Davies R, Cetinkaya-Fisgin A, et al. (2026). Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration. Journal of the Peripheral Nervous System. https://pubmed.ncbi.nlm.nih.gov/41502156/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.